Adiso - Model ADS051 - Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2 release of HXA3 gradient, while also blocking FPR1 activation of neutrophils within the colonic epithelium.  Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study, ADS051 was safe and well-tolerated and restricted to the gut with limited systemic exposure.